<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00081783</url>
  </required_header>
  <id_info>
    <org_study_id>XT009</org_study_id>
    <nct_id>NCT00081783</nct_id>
  </id_info>
  <brief_title>Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients</brief_title>
  <official_title>A Phase II Study of Xcellerated T CellsTM in Patients With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xcyte Therapies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xcyte Therapies</source>
  <brief_summary>
    <textblock>
      This is a Phase II single arm study of a novel T cell immunotherapy in patients with indolent
      non-Hodgkin’s lymphoma (NHL). Eligible patients will have relapsed or refractory disease
      after receiving at least one and no more than four prior regimens. Patients will receive
      Xcellerated T CellsTM, an ex vivo activated and expanded autologous T cell product, in an
      attempt to enhance immune responses with anti-tumor activity. The primary endpoint of the
      study is to evaluate the efficacy of Xcellerated T Cells in patients with indolent NHL.
      Secondary endpoints are to evaluate the safety of the therapy in this patient population, and
      to evaluate changes in the number and phenotype of T- and B-lymphocytes, as well as changes
      in the T cell receptor repertoire, hemoglobin levels, platelet counts and quantitative
      immunoglobulin levels. In a subset of patients, fine-needle aspirates of malignant lymph
      nodes will be performed to assess changes in the lymphocyte composition and phenotype. Bone
      marrow aspirates will be similarly evaluated. Finally, anti-tumor immune responses will be
      evaluated in patients amenable to biopsy of enlarged lymph nodes.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2004</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xcellerated T Cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indolent non-Hodgkin’s Lymphoma (NHL), with one of the following subtypes according to
             the REAL Classification: follicular lymphoma, small lymphocytic lymphoma (SLL),
             extranodal marginal zone B-cell lymphoma (MALT), nodal marginal zone B-cell lymphoma
             (monocytoid B-cell lymphoma), splenic marginal zone lymphoma (splenic lymphoma with
             villous lymphocytes) and mantle cell lymphoma. Other subtypes require approval of the
             Medical Monitor. At least 16 patients with small lymphocytic lymphoma, and no more
             than eight patients with mantle cell lymphoma will be enrolled.

          -  Stage III or IV disease at any time in the past

          -  Relapsed or refractory disease following most recent treatment. Patients are
             considered to have refractory disease if their last treatment course did not result in
             a complete or partial response, or if time to disease progression was six months or
             less. Patients are considered to have relapsed disease if time to disease progression
             is more than six months. Patients who have achieved a partial or complete response
             following most recent therapy must have demonstrated progressive disease.

          -  Patients must have received at least one prior course of systemic therapy for NHL and
             no more than four prior courses of therapy. Repeat courses of the same therapeutic
             regimen separated in time by six or more months are considered separate treatment
             courses, with the exception of single-agent rituximab. Patients with more than four
             prior courses of therapy may be enrolled at the discretion of the Medical Monitor
             after discussion with the Investigator.

          -  Radiographically bi-dimensionally measurable disease. Imaging need not be performed
             within 15 days prior to registration. Prior scans are acceptable provided that there
             has been no intervening therapy for NHL. Scans will be obtained at baseline, following
             registration.

          -  Age of at least 18 years

          -  ECOG performance status of 0 to 2

          -  White blood count (WBC) ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1000/mm3

          -  CD3+ &gt; 1% of total peripheral white blood cell count by flow cytometry

          -  Platelet count &gt; 50,000/mm3

          -  Hemoglobin ³ 10.0 g/dL. Transfusion with red blood cells or use of erythropoietin is
             permissible.

          -  Serum total bilirubin and alanine aminotransferase (ALT) ≤ 2.0 times the upper limit
             of normal

          -  Serum creatinine ≤ 2.0 mg/dL

          -  Serum human anti-mouse antibody (HAMA) titer undetectable or within the normal range,
             and no history of symptomatic allergic reactions to mice or murine (mouse) proteins.
             Patients with elevated HAMA levels may be enrolled at the discretion of the Medical
             Monitor after discussion with the Investigator.

          -  Negative test results for current/active infection with HIV-1, HIV-2, HTLV-1, HTLV-2,
             hepatitis B and hepatitis C within 30 days of registration. (Antibody, antigen and
             nucleic acid tests acceptable, depending on institutional standards)

          -  Women of childbearing potential must have a negative serum pregnancy test. Both men
             and women agree to use a medically accepted form of contraception from the time of
             initial screening through completion of the study.

          -  Able to comprehend and provide signed informed consent

        Exclusion Criteria:

          -  Evidence of Hodgkin’s lymphoma, Burkitt’s lymphoma, diffuse large B-cell lymphoma,
             primary mediastinal B-cell lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia,
             primary central nervous system lymphoma or any other aggressive lymphoma

          -  Any T cell lymphoma

          -  Evidence of primary cutaneous anaplastic large cell lymphoma, Richter’s Syndrome,
             large granular lymphocytosis and Sézary-cell leukemia. Patients with a prior diagnosis
             of chronic lymphocytic leukemia, as evidenced by absolute peripheral lymphocyte count
             of greater than 5,000 per mm3 at any time in the past, are not eligible.

          -  Leukemic manifestations of non-Hodgkin’s lymphoma. Small lymphocytic lymphoma patients
             with peripheral lymphocyte count greater than 5,000 per mm3

          -  Receipt of any chemotherapy, monoclonal antibody, investigational or other systemic
             therapy (except glucocorticoids as noted below) for the treatment of NHL within 2
             months prior to registration

          -  Receipt of glucocorticoids (with the exception of inhaled glucocorticoids) within 1
             month prior to registration

          -  Receipt of intravenous immunoglobulin (IVIG) within 1 month of registration

          -  Registration for, or plans to participate in, any other clinical trial of an
             investigational agent concurrently with this trial

          -  History of malignancy other than NHL within five years of registration, except
             adequately treated basal or squamous cell skin cancer or in situ carcinoma of the
             cervix. Other exceptions must be approved by the Xcyte Therapies’ Medical Monitor
             prior to registration.

          -  Infection requiring treatment with antibiotics, antifungal, or antiviral agents within
             seven days of registration

          -  Active autoimmune disease requiring systemic treatment

          -  Major organ system dysfunction including (but not limited to): New York Heart
             Association Class III or IV, severe pulmonary, renal, hepatic, gastrointestinal,
             neurologic or psychiatric dysfunction which would impair patient’s ability to
             participate in the trial

          -  Any other pertinent medical or psychological condition which leads the Investigator to
             believe the study would not be appropriate treatment or in the patient’s best interest
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark W. Frohlich, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Xcyte Therapies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vicki M. Mizuno</last_name>
    <phone>206-262-6251</phone>
    <email>vmizuno@xcytetherapies.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Cancer Care</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Chang</last_name>
      <phone>415-925-5040</phone>
      <email>JChang@cal-cancer-care.com</email>
    </contact>
    <investigator>
      <last_name>Jennifer B. Lucas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lynne Smith</last_name>
      <phone>323-865-0371</phone>
      <email>diansmi@usc.edu</email>
    </contact>
    <investigator>
      <last_name>Ann Mohrbacher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vineeta Prasad</last_name>
      <phone>858-822-0337</phone>
      <email>vprasad@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Januario E. Castro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Wood</last_name>
      <phone>858-939-5062</phone>
      <email>cathy.wood@sharp.com</email>
    </contact>
    <investigator>
      <last_name>Charles Redfern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Zhang</last_name>
      <phone>415-476-3741</phone>
      <email>jzhang@medicine.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Lawrence D. Kaplan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juli Murphy, BS, CCRC</last_name>
      <phone>303-285-5087</phone>
      <email>juli.murphy@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Peter McSweeney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Cancer Care</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Andrews</last_name>
      <phone>404-851-2359</phone>
      <email>kandrews@atlantacancercare.com</email>
    </contact>
    <investigator>
      <last_name>Ronald G. Steis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Newton, RN</last_name>
      <phone>410-502-7985</phone>
      <email>meusesu@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Ian W. Flinn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Cancer &amp; Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Bongiorno, RN, BSN</last_name>
      <phone>301-571-0019</phone>
      <email>nbongiorno@ccbdmd.com</email>
    </contact>
    <investigator>
      <last_name>Ralph V. Boccia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Boyajian</last_name>
      <phone>617-632-3352</phone>
      <phone_ext>42314</phone_ext>
      <email>Richard_Boyajian@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Arnold Freedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Bryan</last_name>
      <phone>314-362-6359</phone>
      <email>kbryan@im.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy L. Bartlett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Martin</last_name>
      <phone>732-235-8995</phone>
      <email>martinj4@umdnj.edu</email>
    </contact>
    <investigator>
      <last_name>Roger K. Strair, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Weiss</last_name>
      <phone>614-293-3437</phone>
      <email>Weiss-3@medctr.osu.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aubyn Grant, CCRP</last_name>
      <phone>503-494-5074</phone>
      <email>granta@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Brandon Hayes-Lattin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Williams, RN</last_name>
      <phone>864-241-6251</phone>
      <email>kimberly.williams@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Joe J. Stephenson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Ayala</last_name>
      <phone>713-792-3610</phone>
      <email>abayala@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Peter W. McLaughlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toni Oien, CCRC</last_name>
      <phone>206-386-2831</phone>
      <email>toni.oien@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Michael S. Milder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Perrault-Gray</last_name>
      <phone>206-583-6559</phone>
      <phone_ext>61870</phone_ext>
      <email>Aimee.PerraultGray@vmmc.org</email>
    </contact>
    <investigator>
      <last_name>David M. Aboulafia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2004</study_first_submitted>
  <study_first_submitted_qc>April 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2004</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>T Cells</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>NHL</keyword>
  <keyword>Xcellerated T Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

